Takeaways HEMGENIX has moved from theory to practice in Canada, with the first patient now treated outside a trial and public funding in place in Ontario and British Columbia. Market‑wise,...
Takeaways: BC’s decision makes REVESTIVE a province‑funded option for both adult and pediatric Short Bowel Syndrome patients who depend on parenteral support, align...
Takeaways: Fabhalta gives Novartis a first‑in‑class, oral, mechanism‑targeted therapy in a tiny but high‑need C3G population, creating a premium niche nephrology revenue stream anchored on...
Takeaways: Cysklar gives Canada’s small cystinosis community a dedicated, easy‑to‑use cysteamine eye‑drop option for corneal crystals, strengthening Leadiant’s rare‑disease ...
Takeaways: Health Canada’s CTA clearance positions Affinia among the first wave of next‑gen cardiac gene therapy players, using a bespoke AAV capsid to go after genetically defined BAG...
